ReviewHuman vaccines & immunotherapeutics2019
IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Trial
- Immunoglobulin Y protects intestinal epithelium and modulates gut microbiota.Microbiome research reports · 2026Article
- Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Production, purification, and characterization of chicken immunoglobulin Y anti-Open veterinary journal · 2026Article
- Therapeutic applications of IgY in common canine and feline viral diseases.Veterinary and animal science · 2025Review
- Article
- Mass production of IgY-containing tablets for COVID-19 transmission control.Scientific reports · 2025Article
- Harnessing the Potential of IgY: A Creative Approach for Immunodiagnosis and Immunotherapy Against Viral Diseases of Animals.Current microbiology · 2025Review
- A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.Antibody therapeutics · 2025Review
- Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025Review
- Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections.Frontiers in immunology · 2025Review
- IgY-mediated protection againstBioImpacts : BI · 2025Article
- Amelioration of LPS-Induced Jejunum Injury and Mucus Barrier Damage in Mice by IgY Embedded in W/O/W Emulsion.Foods (Basel, Switzerland) · 2024Article
- Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2 in Syrian Hamster Models.Vaccines · 2024Article
- Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles againstHeliyon · 2024Article
- Effects of Chicken Egg Powder, Bovine Colostrum, and Combination Therapy for the Treatment of Gastrointestinal Disorders.Nutrients · 2024Review
- Protective Effect of IgY Embedded in W/O/W Emulsion on LPS Enteritis-Induced Colonic Injury in Mice.Nutrients · 2024Article
- Biosafety and immunology: An interdisciplinary field for health priority.Biosafety and health · 2024Review
- Generation of chicken-based IgY polyclonal antibodies againstToxicon: X · 2024Article
- Comparison of immunoglobulin Y antibody production in new and spent laying hens.Veterinary world · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of drug resistance among the causative organisms for respiratory tract infections represents a critical challenge to the global health care community. Further, although vaccination can prevent disease, vaccine development is impeded by several factors. Therefore, novel approaches to treat and manage respiratory infections are urgently needed. Passive immunization represents a possible alternative to meet this need. Immunoglobulin Y antibodies (IgYs) from the yolk of chicken eggs have previously been used against bacterial and viral infections in human and animals. Their advantages include lack of reaction with mammalian Fc receptors, low production cost, and ease of extraction. Compared to mammalian IgGs, they have higher target specificity and greater binding avidity. They also possess remarkable pathogen-neutralizing activity in the respiratory tract and lungs. In this review, we provide an overview of avian IgYs and describe their potential therapeutic applications for the prevention and treatment of respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.